Xarelto Paediatric VTE PASS Drug Utilization Study: An Observational, Longitudinal, Multi-source Drug Utilization Safety Study to Evaluate the Drug Use Patterns and Safety of Rivaroxaban Oral Suspension in Children Under Two Years With Venous Thromboembolism

This is an observational study in which only data are collected from participants receiving their usual treatment. The study is done in children under 2 years old with venous thromboembolism (VTE).
VTE is a condition in which blood clots form in the veins, usually in the leg. This can cause pain and swelling. The clot can also break apart and travel in the blood to the lungs where it can block the blood flow. This can be life threatening.
Rivaroxaban is approved for doctors to prescribe to children with VTE, but there is limited information about how it is used, how well it works, and how safe it is in children under 2 years old. Children in this study are already receiving or will receive rivaroxaban or other currently used medicines for VTE from their doctor according to the approved product information.
The purpose of this study is to collect information on the pattern of use and safety of rivaroxaban and other standard medicines for VTE in children under 2 years old.
The main information that researchers will collect in this study:
* Age, gender, and other information about the child and their illness
* Type of VTE treatment given to the child
* Occurrence of medically important bleeding and its severity
Further information that researchers will collect:
* Changes in the characteristics of the children given VTE treatment (e.g., changes in the age range of children given VTE treatment) and changes in the treatment pattern for VTE
* Return of VTE symptoms
* Types of doctors who prescribe VTE treatment and their set-up (e.g., special clinics versus hospitals) Besides this data collection, no further tests or examinations are needed in this study.
The data for this study will be collected from electronic health records and health insurance claims data until 2026.
Researchers will observe each child during treatment until:
* end of the anticoagulation treatment period e.g. discontinuation of all study drugs,
* their information is no longer available, or
* the study ends.

Start Date01 Sep 2026

Sponsor / Collaborator

Bayer AG

[+1]

NCT07228663

/ Not yet recruitingPhase 3IIT

Rivaroxaban Plus Acetylsalicylic Acid Versus Standard of Care for Arterial and Venous Cardiovascular Prevention After Hip Fracture Surgery in Patients With Myocardial Injury: a Pilot Randomized Trial

A third of patients undergoing surgery for a hip fracture develop a myocardial injury (i.e., an elevated troponin measurement), and these patients are at substantial risk of death and morbidity. Current prophylaxis strategies focus on preventing venous thromboembolism (VTE); however, arterial events are more common and carry a poor prognosis. The association of acetylsalicylic acid (ASA) 75-100 mg once daily and rivaroxaban 2.5 mg twice a day (the regimen used in the COMPASS trial) might prevent both VTE and arterial cardiovascular events. Among patients who have undergone hip fracture surgery and have evidence of myocardial injury, to explore the feasibility of a randomized controlled trial (RCT) comparing rivaroxaban 2.5 mg twice daily + low-dose ASA (75-100 mg) for 90 days, with standard VTE thromboprophylaxis for 30 days, for prevention of major cardiovascular events. The HIPSTER-Pilot is a multicenter, international, open-label, pilot RCT with blinded outcome adjudication. A total of 100 participants aged ≥45 years who received hip fracture surgery and experienced a myocardial injury will be randomized to receive either rivaroxaban 2.5 mg twice daily plus ASA 75-100 mg daily for 90 days or standard VTE prophylaxis with an anticoagulant for 30 days. The primary feasibility outcome will be the recruitment rate. Other feasibility measures include completeness of follow-up and adherence to the treatment. Exploratory clinical outcomes will be assessed. This pilot trial will provide information on the feasibility of conducting a larger RCT to evaluate the efficacy and safety of the COMPASS regimen for preventing arterial and venous thrombotic events after hip fracture surgery in patients who have had myocardial injury. The results of this feasibility study will inform the design of the full-scale trial.

Start Date01 Dec 2025

Sponsor / Collaborator

McMaster University

NCT07246005

/ Not yet recruitingPhase 2

A Randomised Pilot Study Assessing the Optimal Duration of Anticoagulation for Left Ventricular Thrombus

The LVT DURATION (Optimal Duration of Anticoagulation for LV Thrombus) is a pilot study planned to assess the practicalities of conducting a randomised control trial (RCT) whilst establishing data around the ideal duration of anticoagulation in the treatment of LV thrombus. The main objectives of the study are:
* To assess the practicalities of conducting an RCT with regard to recruitment, retention, and outcome measurement.
* To identify the optimal length of anticoagulation in the treatment of LV Thrombus
After randomisation participants will:
* Continue their prescribed oral anticoagulant for the remainder of the trial
* Discontinue their prescribed oral anticoagulant for the remainder of the trial

Start Date01 Dec 2025

Sponsor / Collaborator

Queen Mary University of London

100 Clinical Results associated with Rivaroxaban

100 Translational Medicine associated with Rivaroxaban

100 Patents (Medical) associated with Rivaroxaban

9,058

Literatures (Medical) associated with Rivaroxaban

01 Jan 2026·JOURNAL OF ETHNOPHARMACOLOGY

Study on the mechanism of Huoxue Jiedu decoction in the intervention of phosphatidylinositol 3-kinase/serine-threonine kinase/nuclear factor-kappa B pathway in the treatment of deep vein thrombosis

Article

Author: Zhang, Sixiang ; Li, Yuhuan ; Wang, Yingrui ; Liu, Zixuan ; Guo, Bingqi ; Zhao, Youmin ; Liu, Zheng

OBJECTIVE:

This study aimed to investigate the therapeutic effects and underlying molecular mechanisms of HXJDT in the treatment of DVT.

METHODS:

A DVT model was established via the inferior vena cava stenosis method to evaluate the therapeutic effect of HXJDT. Vascular morphology following modeling was examined by hematoxylin-eosin (HE) staining, and the expression differences of M1 and M2 macrophages during thrombus formation were explored by immunohistochemistry. The expression levels of pathway-related proteins and genes were measured using ELISA kits, Western blotting, and quantitative real-time PCR (qPCR).

RESULTS:

This study revealed that the PI3K/Akt/NF-κB signaling pathway was highly expressed in the DVT model. It promoted macrophage recruitment, activated the expression of downstream pro - inflammatory factors (TNF-α, IL-6), upregulated the expression of PAI-1, and downregulated the expression of IL-10 and t-PA, thereby inhibiting thrombus dissolution. PTEN, a negative regulator of the PI3K/Akt/NF-κB pathway, exhibited decreased expression in DVT. Meanwhile, the lncRNA GAS5/miRNA-21 sponge mechanism also played an important role in DVT progression. HXJDT significantly ameliorated the pathogenesis processes of DVT. Notably, the therapeutic effect of high-concentration HXJDT was superior than that of rivaroxaban tablets.

CONCLUSION:

In conclusion, HXJDT regulates the lncRNA GAS5/miRNA-21/PTEN axis to suppress the PI3K/Akt/NF-κB pathway, thereby ameliorating DVT and improving prognosis, which highlights its potential clinical value.

01 Jan 2026·INTERNATIONAL JOURNAL OF CARDIOLOGY

Clinical impact of kidney function in patients with atrial fibrillation receiving oral anticoagulants

Article

Author: Nagashima, Kouichi ; Sakamoto, Daisuke ; Okumura, Yasuo ; Watanabe, Ryuta ; Sotomi, Yohei ; Matsuoka, Yuki ; Sunaga, Akihiro ; Higuchi, Yoshiharu ; Nakatani, Daisaku ; Kanda, Takashi ; Kitamura, Tetsuhisa ; Okada, Katsuki ; Minamiguchi, Hitoshi ; Sakata, Yasushi

BACKGROUND:

Renal function influences the pharmacokinetics of oral anticoagulants in atrial fibrillation (AF), potentially affecting both efficacy and bleeding risk. However, its differential impact across specific agents remains unclear. In this study, we aimed to evaluate the association between renal function and ischemic and bleeding risks in patients with AF, with analyses stratified by anticoagulant type.

METHODS:

We analyzed 7239 patients with non-valvular AF from the DIRECT-Extend registry, a pooled dataset of three large-scale registries. Creatinine clearance (CrCl) was calculated using the Cockcroft-Gault formula and categorized into ≥50, 30 to <50, and 15 to <30 mL/min. The primary ischemic endpoint was stroke or systemic embolism, and the primary bleeding endpoint was major bleeding. Cox proportional hazard models and restricted cubic spline analyses assessed associations between CrCl and outcomes, with subgroup analyses by anticoagulant type.

RESULTS:

Lower CrCl was associated with older age, female sex, and greater comorbidity burden. Impaired renal function was significantly associated with higher ischemic and bleeding risks. Spline analysis demonstrated a continuous increase in both risks with declining CrCl, with a nonlinear relationship for bleeding. Subgroup analyses revealed significant associations between reduced CrCl and ischemic risk in patients on dabigatran, rivaroxaban, edoxaban, and warfarin. Increased bleeding risk was evident for edoxaban and warfarin at lower CrCl levels. No significant association was observed between CrCl and either endpoint in patients receiving apixaban.

CONCLUSION:

In this large real-world cohort, declining renal function was associated with increased ischemic and bleeding risks, highlighting the importance of renal function-based risk assessment in the management of anticoagulation therapy.

31 Dec 2025·JOURNAL OF MEDICAL ECONOMICS

Nationwide extrapolation of economic benefit of therapeutic innovation: a 10-year retrospective budget impact of direct oral anticoagulants introduction in France

Article

Author: Belhassen, M. ; Lesage, H. ; Moreau, R. ; Guilmet, C. ; Cotté, F. E. ; Née, M. ; Danchin, N. ; Marant Micallef, C. ; Guitard-Dehoux, D.

OBJECTIVES:

Patients with atrial fibrillation (AF) face increased risks of strokes and systemic thromboembolism (SE), traditionally managed with vitamin K antagonists (VKAs), which are associated with major bleeding (MB) risks. The nationwide real-life data-based NAXOS study, comparing Direct Oral Anticoagulants (DOACs: apixaban, dabigatran, rivaroxaban) to VKAs in over 400,000 AF patients in France, showed that DOACs are more effective, safer, and associated with lower total costs. This study evaluates the 10-year budget impact of DOACs in France, focusing on reductions in strokes/SE, MB, and monitoring costs (INRt).

METHODS:

A retrospective budget impact model from 2014 to 2023 compared scenarios with and without DOACs, using clinical and cost data from the NAXOS study. The target population of DOAC-eligible patients ranged from 725,000 in 2014 to 1.4 million in 2023. Market shares trends were derived from the public national drugs database, indicating that VKAs' use decreased from 67% to 11%, while DOACs, especially apixaban, rose sharply (2% to 55%) over the same period. Costs included treatment acquisition, strokes/SE, MB, and international normalized ratio testing (INRt) for VKAs.

RESULTS:

Over a 10-year horizon, the introduction of DOACs is estimated to have prevented 73,009 strokes, 97,234 major bleeding, and 19,567 stroke-related deaths among patients with NVAF. DOAC introduction increased treatment costs by €5.15 billion over 10 years, and reduced costs for strokes/SE (-€4.24 billion), MB (-€3.22 billion), and INRt (-€1.14 billion), leading to €3.45 billion of savings for National Insurance over 10 years, with apixaban contributing 55% of savings.

LIMITATIONS:

This analysis may not account for all contextual variables, such as indirect costs related to productivity losses.

CONCLUSION:

Over 10 years, the introduction of DOACs in France has generated substantial savings in AF-related costs, highlighting their clinical and economic benefits and the importance for authorities to valorise the external effects of therapeutic innovations.

326

News (Medical) associated with Rivaroxaban

30 Dec 2025

·firstwordpharma.com

'Threadbare administrative record': Federal judge stops 340B rebate pilot

Just days before the US Health Resources and Services Administration (HRSA) was set to launch a pilot evaluating a rebate-based model of the 340B discount programme, its rollout has been blocked by a federal judge.The American Hospital Association (AHA), along with the Maine Hospital Association and four safety-net hospitals, filed suit at the beginning of December to block the pilot's Jan. 1, 2026 launch, arguing that a rebate system "would inflict hundreds of millions of dollars’ worth of annual costs on hospitals." Judge Lance Walker of the US District Court for the District of Maine sided with the plaintiffs on Monday, issuing an injunction against the pilot as its "economic impact and disruption to services is substantial and… sufficient to demonstrate irreparable injury."Rebate pushCurrently, 340B-eligible hospitals — which serve uninsured and low-income patients — receive significant discounts on drugs upfront, but drugmakers have argued that the programme is rife with abuse, and that large hospital systems exploit the discounts by inflating prices for both uninsured patients and insurers. And for drugs set to debut lower Medicare prices next year thanks to negotiations under the Inflation Reduction Act (IRA), pharmaceutical companies are concerned their products may be subjected to duplicative price concessions if they are also purchased at the 340B price. To avoid potential abuse and "double-dipping," several pharmas, including Johnson & Johnson, Eli Lilly and Bristol Myers Squibb have pushed to adopt a model where hospitals would be required to pay the full amount of a drug upfront, then file for a rebate afterwards. Though their efforts to move to a rebate model were initially rebuffed, HRSA announced in July it would launch a pilot programme "to test…in a methodical and thoughtful approach…a fair and transparent 340B rebate model process." In October, nine therapeutics were accepted for the pilot, including three from J&J: Stelara (ustekinumab), an IL-12/IL-23 inhibitor approved for several autoimmune diseases; oral anticoagulant Xarelto (rivaroxaban); and blood cancer treatment Imbruvica (ibrutinib), which it co-commercialises with AbbVie. Other pilot participants include BMS's anticoagulant Eliquis (apixaban), Boehringer Ingelheim and Eli Lilly's diabetes and heart failure treatment Jardiance (empagliflozin), Merck & Co.'s diabetes drug Januvia (sitagliptin), Novo Nordisk's NovoLog family of insulin products, AstraZeneca's diabetes drug Farxiga (dapagliflozin), and Amgen's Enbrel (etanercept), which is used to treat chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis and juvenile idiopathic arthritis. Each product selected for the 340B rebate model pilot was also part of the first round of Medicare price negotiations, which is also set to go into effect on Jan. 1, 2026.'Fatal' errorWhile the Administrative Procedure Act (APA) provides a pathway for US agencies to launch new programmes, it requires that the same be "reasonable and reasonably explained," with an agency tasked with keeping a "record of the relevant factors it considered and…a reasoned explanation for its course of action."However, Walker found that HRSA's rebate pilot did not meet these "vanishingly minimal requirements.""The Agency’s roll out has involved a rather threadbare administrative record that likely fails to consider and reasonably explain the impact of a rebate model on 340B hospitals, who rely on upfront price concessions to stretch few resources as far as possible to serve rural and poor communities," he wrote in his ruling. In the suit, AHA claimed that a rebate model would "impose vast administrative costs to submit, track, recover, and potentially dispute the rebates," while also draining hospitals "of huge sums of money through payments to drug companies that the hospitals then must wait to have refunded," and which drugmakers "have every incentive to slow and stymie the issuance of rebates." Walker took issue with the fact that HRSA is still evaluating administrative costs of its pilot. "This failure to consider administrative costs before approving the manufacturers’ applications under the Rebate Program is fatal under the APA," he concluded. "Defendants cannot fly the plane before they build it."

AHA

22 Dec 2025

·www.einpresswire.com

Update on the Safety of Andexxa by AstraZeneca: FDA Safety Communication

AUDIENCE: Patient, Health Care Professional, Pharmacy, Hematology ISSUE: Since approval, the FDA has received postmarketing safety data on thromboembolic events, including serious and fatal outcomes, in patients treated with Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo). Based on available data, the serious risks including the increase in thromboembolic events are such that the FDA considers the risks of the product to outweigh its benefits. The FDA has communicated this position to AstraZeneca, and the company has submitted a request to voluntarily withdraw the BLA for the product for commercial reasons. Additionally, the company has confirmed that it will end U.S. commercial sales today, December 22, 2025. Andexxa will no longer be manufactured for or sold in the U.S. by AstraZeneca after December 22, 2025. Continuous monitoring and assessment of the safety of all biological products, including Andexxa, is an FDA priority, and we remain committed to informing the public when we learn new information about these products. BACKGROUND: The FDA initially granted accelerated approval (AA) of Andexxa, a recombinant modified human factor Xa (FXa) protein, in 2018, indicated for patients treated with rivaroxaban or apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding. Initial approval included a Boxed Warning for thromboembolic risks. AA was granted based on the change from baseline in anti-activated FXa (anti-FXa) activity in healthy volunteers, as a surrogate endpoint reasonably likely to predict clinical benefit. At the time of AA of Andexxa, AstraZeneca (Applicant) was subject to a requirement to conduct a randomized controlled trial (NCT03661528) to verify the clinical benefit of Andexxa among patients with intracerebral hemorrhage following treatment with rivaroxaban or apixaban. On January 31, 2024, the Applicant submitted a supplemental Biologics Licensing Application (sBLA) for Andexxa with the results of the ANNEXA-I trial to fulfill this requirement. The FDA convened a meeting of the Cellular, Tissue, and Gene Therapies Advisory Committee (AC) on November 21, 2024 1 , to discuss the results of the ANNEXA-I trial. The major safety findings discussed at the AC meeting included a doubling of the rate of thromboses and thrombosis-related deaths at Day 30 in the Andexxa arm compared with usual care (UC): Increased risk of thrombosis: ANNEXA-I demonstrated an increased incidence of thrombosis (14.6% versus 6.9%) and thrombosis-related deaths at Day 30 (2.5% versus 0.9%) in the Andexxa arm compared with the UC arm, respectively. Death related to thrombotic events through 30 days occurred in 6 patients (2.5%) in the Andexxa arm compared with 2 patients (0.9%) in the usual care control arm. The FDA will continue working with AstraZeneca to keep providers and the public informed as AstraZeneca prepares to end sale of Andexxa. 1 Cellular, Tissue, and Gene Therapies Advisory Committee November 21, 2024 Meeting Announcement [ FDA Safety Communication - 12/18/2025] Content current as of: 12/19/2025 Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Clinical ResultDrug ApprovalAccelerated ApprovalGene TherapyClinical Study

19 Dec 2025

·www.fiercepharma.com

AstraZeneca to pull bleeding reversal agent Andexxa after FDA flags risk imbalance

The FDA said it believes the risks of Andexxa outweigh its benefits. AstraZeneca is responding by pulling the medicine from the market. Seven years after the FDA's accelerated approval of bleeding reversal agent Andexxa, which was then under the ownership of Portola Pharmaceuticals, the drug's round trip on the U.S. market is coming to an end. Andexxa, now under AstraZeneca's stewardship, is slated to be pulled from the U.S. market next week, according to a Dec. 18 update from the FDA. In the FDA communication, the agency notes that it has "received postmarketing safety data on thromboembolic events, including serious and fatal outcomes, in patients treated with Andexxa." Based on the available data, the agency "considers the risks of the product to outweigh its benefits," it said.The FDA has shared that position with AstraZeneca, and the company "submitted a request to voluntarily withdraw the BLA for the product for commercial reasons," the agency said.Andexxa won its original approval as a treatment for patients on the popular blood thinners Eliquis and Xarelto who needed anticoagulation due to life-threatening or uncontrolled bleeding, with a boxed warning describing the risk of thromboembolic events.While AstraZeneca in 2023 touted the efficacy results of a postmarketing study, that trial recorded a doubling in the rate of thromboses and thrombosis-related deaths at day 30 for patients who received Andexxa versus those who received standard care, according to the FDA.An FDA advisory panel last year scrutinized the drug's postmarketing data, and the agency later rejected AstraZeneca's application to convert the accelerated approval into a full nod. At that time, AstraZeneca said it planned to keep the drug on the market.On Friday, an AstraZeneca spokesperson said the company is "confident that Andexxa has a positive benefit risk profile for eligible patients with life-threatening or uncontrolled bleeds.""In discussions with the FDA, alignment on a feasible path to convert Andexxa from accelerated to traditional approval in the U.S. could not be reached," the spokesperson added. Portola scored accelerated approval for the drug in 2018 after a pair of prior regulatory setbacks. Rare disease drugmaker Alexion scooped up Portola for $1.4 billion in 2020, and AstraZeneca came in afterward with its massive Alexion buyout. Last year, AstraZeneca reported full-year Andexxa sales of $219 million.

Drug ApprovalAcquisitionAccelerated Approval

100 Deals associated with Rivaroxaban

External Link

KEGG	Wiki	ATC	Drug Bank
D07086	Rivaroxaban	B01AF01	DB06228

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Thromboembolism	Japan	Bayer Yakuhin Ltd.	24 Nov 2023
Thrombosis	United States	Janssen Pharmaceuticals, Inc.	20 Dec 2021
Atherosclerosis	European Union	Viatris Ltd. (New Zealand)	12 Nov 2021
Atherosclerosis	Iceland	Viatris Ltd. (New Zealand)	12 Nov 2021
Atherosclerosis	Liechtenstein	Viatris Ltd. (New Zealand)	12 Nov 2021
Atherosclerosis	Norway	Viatris Ltd. (New Zealand)	12 Nov 2021
Atrial Fibrillation	China	Bayer AG	31 Mar 2009
Myocardial Infarction	Australia	Bayer Australia Ltd.	24 Nov 2008
Recurrent deep vein thrombosis	Australia	Bayer Australia Ltd.	24 Nov 2008
Stroke	Australia	Bayer Australia Ltd.	24 Nov 2008
Systemic embolism	Australia	Bayer Australia Ltd.	24 Nov 2008
Acute Coronary Syndrome	European Union	Bayer AG	30 Sep 2008
Acute Coronary Syndrome	Iceland	Bayer AG	30 Sep 2008
Acute Coronary Syndrome	Liechtenstein	Bayer AG	30 Sep 2008
Acute Coronary Syndrome	Norway	Bayer AG	30 Sep 2008
Embolism	European Union	Bayer AG	30 Sep 2008
Embolism	Iceland	Bayer AG	30 Sep 2008
Embolism	Liechtenstein	Bayer AG	30 Sep 2008
Embolism	Norway	Bayer AG	30 Sep 2008
Peripheral arterial occlusive disease	European Union	Bayer AG	30 Sep 2008

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cardiovascular Diseases	Phase 3	Australia	Bayer AG	14 Dec 2020
Cardiovascular Diseases	Phase 3	Belgium	Bayer AG	14 Dec 2020
Cardiovascular Diseases	Phase 3	Canada	Bayer AG	14 Dec 2020
Cardiovascular Diseases	Phase 3	France	Bayer AG	14 Dec 2020
Cardiovascular Diseases	Phase 3	Germany	Bayer AG	14 Dec 2020
Cardiovascular Diseases	Phase 3	India	Bayer AG	14 Dec 2020
Cardiovascular Diseases	Phase 3	Malaysia	Bayer AG	14 Dec 2020
Cardiovascular Diseases	Phase 3	Nepal	Bayer AG	14 Dec 2020
Cardiovascular Diseases	Phase 3	Saudi Arabia	Bayer AG	14 Dec 2020
Cardiovascular Diseases	Phase 3	Singapore	Bayer AG	14 Dec 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


PREVAPIX-ALL (ASH2025)	Not Applicable	-	19	DOAC	ntvhkvuygr(srxcpgwyoe) = hjvaemfjtk kkpfkfdvjg (szrehcymem ) View more	Positive	06 Dec 2025
ASH2025	Not Applicable	Atrial Fibrillation	32,294	Apixaban or Rivaroxaban with Amiodarone	cmoklcfodx(xcrcuxktep) = tqppmfnsfj xqnmcqvzrt (vurthjfjiq )	Positive	06 Dec 2025
				Apixaban or Rivaroxaban with Flecainide or Sotalol	cmoklcfodx(xcrcuxktep) = bqnwhdtbhy xqnmcqvzrt (vurthjfjiq )
NCT02168829 (OCEAN, Pubmed \| N Engl J Med)	Phase 4	Atrial Fibrillation	1,284	Rivaroxaban 15 mg	gjrrxyupgs(pxwcfzqutz) = zgcelkqktm akxmqypgqf (upkrmxwweu ) View more	Negative	08 Nov 2025
				Aspirin 70-120 mg	gjrrxyupgs(pxwcfzqutz) = fynqebcmoy akxmqypgqf (upkrmxwweu ) View more
NCT02504216 (VOYAGER PAD, Pubmed \| J Am Heart Assoc)	Phase 3	Peripheral Arterial Disease	2,370	Rivaroxaban 2.5 mg	lvqducmgqh(jefjjpjafw): win ratio = 1.16 (95.0% CI, 1.03 - 1.3), P-Value = 0.0167	Positive	04 Nov 2025
				Placebo
NCT06371170 (Pubmed \| Thromb Res)	Not Applicable	-	18	Rivaroxaban	zfkfnuomsu(wllmccrewv) = 67% in warfarin group gypxamsnqy (mfixaapqaz ) View more	Positive	01 Sep 2025
				Warfarin
NCT04970576 (Pubmed \| JACC Adv)	Phase 4	Thrombosis	261	Rivaroxaban 20 mg daily	zgvueocwno(wciarvehyr) = vzdnuwonee dwvdogzndz (enbfgreyob ) View more	Positive	01 Aug 2025
				Warfarin (target international normalized ratio 2-3)	zgvueocwno(wciarvehyr) = xyetwuyltf dwvdogzndz (enbfgreyob ) View more
NCT04755283 (AZALEA-TIMI 71 \| AZALEA-TIMI 71, CTgov)	Phase 2	Stroke \| Atrial Fibrillation	1,287	Abelacimab (Abelacimab 90 mg (MAA868))	vtekzzvxmq = erkokbjxmv pxhrmoflko (eflzmjflvi, cvqmmwzspx - kyjwfekfaf) View more	-	30 Jul 2025
				Abelacimab (Abelacimab 150 mg (MAA868))	vtekzzvxmq = fcvrkmyext pxhrmoflko (eflzmjflvi, dsymmtxlws - uakxezthse) View more
PB3023 (EHA2025)	Not Applicable	Multiple Myeloma	101	NOACs (Apixaban 2.5 mg twice daily, Rivaroxaban 10-20 mg per day)	nowylylbkq(jwvfnmrrdf) = Thromboembolic events were observed in only two patients as acute DVTs tnhtnwszmp (jvcknxrgvf ) View more	Positive	14 May 2025
NCT02234843 (EINSTEIN-Jr, Pubmed) Manual	Phase 3	Venous Thromboembolism	500	rivaroxaban	bcbyjktpbg(vgjxokohdw) = npvtinbpgz swhscqcmpa (egsysgxznq ) View more	Positive	01 May 2025
				standard anticoagulants	-
NCT00440193 \| NCT00403767 \| NCT02064439 \| NCT00439777 \| NCT00439725 (ROCKET-AF;EINSTEIN DVT;EINSTEIN PE;EINSTEIN Extension;EINSTEIN CHOICE, Pubmed \| Drugs Aging)	Phase 3	Atrial Fibrillation \| Venous Thromboembolism	-	Rivaroxaban	aimvblnmij(npbhrrgexi) = upjfbazomq qysohmchjc (krwqyatsmr )	Positive	31 Mar 2025
				Placebo	aimvblnmij(npbhrrgexi) = hehqlpuxgw qysohmchjc (krwqyatsmr )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis